Table 1:
Phenotype | 3XTg | 5XFAD | APPE693Q | APPSWE/PS1ΔE9 | FRAXAD | J20 | R1.40 | Tg2576 | ArcSWE | |
---|---|---|---|---|---|---|---|---|---|---|
Mutated Genes* | APPSWE MAPTP301L PSEN1M146V | APPSWE APPFLOR APPLOND PSEN1M146L PSEN1L286V | APPDUTCH | APP PSEN1ΔE9 | APPSWE Fmr1KO | APPSWE APPIND | APPSWE | APP | APPSWE APPArc | |
APP Gene Contains UTR Sequences | No [133] | Yes [134] | No [59] | Yes [135] | Yes [136] | No [33] | Yes [137] | |||
Early Mortality | Yes [110] | Yes [59] | Yes [59] | |||||||
AGS Susceptibility | Yes [114] | Yes [111] | No [113] | No [113] | Yes [111] | |||||
Anti-Aβ Rescues | Seizures | Yes [114] | Yes [111] | |||||||
Epilepti form Discharge Duration |
Yes [114] | |||||||||
mGlu R5 Inhibitors or Genetic Knockout Rescues | Seizures | Yes [114] | Yes [37] | Yes [37,111] | ||||||
Aβ Levels or Plaques | Yes [61] | Yes [47,61] | Yes [53] | Yes & No** [53] | ||||||
Dendritic spine or synapse loss | Yes [75,86] | |||||||||
Early Mortality | Yes [110] | |||||||||
Epilepti form | Yes [114] | |||||||||
Discharge Duration | ||||||||||
Learning / Memory |
Yes [75] | Yes [47,61,75,86] | ||||||||
Altered Expression of mGluR5 | Yes [73] | Yes [47] | ||||||||
Fmr1 gene Differentially Spliced | Yes [103] | Yes [103] | ||||||||
FMRP Differentially Expressed | No [45] Yes [47] | Yes [46] |
APPSWE = APP KM670/671NL (APP with Swedish familial AD mutation); APPFLOR = APP I716V (APP with Florida familial AD mutation); APPLOND = APP V717I (APP with London familial AD mutation); APPDUTCH = APP E693Q (APP with Dutch familial AD mutation); APPIND = APP V717F (APP with Indiana familial AD mutation); APPARC = APP E693G (APP with Arctic familial AD mutation); MAPT P301L (tau familial AD mutation); PSEN1 (presenilin 1 familial AD mutation).
Human Aβ produced from the transgene is not reduced. Endogenous mouse Aβ is reduced.